Moderna

mRNA cancer vaccines in clinical trials exceed 60, with 2 in Phase III. Expected commercial approval by 2029. US and China lead in trials, with skin cancer dominating. mRNA vaccines promise targeted, personalized cancer treatments.

Moderna's Nova 301 trial, a phase 3 study evaluating mRNA-1403, an investigational norovirus vaccine, has dosed its first US participant. The trial aims to enroll 25,000 participants globally to assess efficacy, safety, and immunogenicity, focusing on older adults at risk of severe norovirus outcomes.

The article discusses the importance of summarizing content accurately and concisely, focusing on retaining original expressions while ensuring clarity.

Resolution Therapeutics secures $85 million in series B financing to advance RTX001, a pro-regenerative macrophage therapy for end-stage liver disease, into clinical trials. RTX001 aims to address severe inflammation and fibrosis, with a phase 1/2 EMERALD trial set to begin in Q4 2024. The financing also supports pipeline growth and manufacturing enhancements.

Pharma companies like Novo Nordisk, Viking Therapeutics, Amgen, and CRISPR Therapeutics are set to announce clinical trial results for next-gen weight loss drugs and a cancer/autoimmune disease cell therapy. Moderna may also launch a new product beyond its COVID-19 vaccine.

Pharma companies like Novo Nordisk, Viking Therapeutics, Amgen, CRISPR Therapeutics, and Moderna are set to announce clinical trial results for next-gen weight loss drugs, cancer and autoimmune therapies, and potential new products beyond COVID-19 vaccines by year-end.

Asia is rapidly becoming a biomanufacturing powerhouse, with countries like China, Singapore, South Korea, and India leading the charge. These nations are investing heavily in infrastructure, fostering innovation, and improving regulatory environments to attract global biopharma investments. The Asia Pacific biopharmaceuticals market is projected to grow significantly, driven by government support, skilled workforce development, and strategic partnerships. Key initiatives include Singapore's BioPIPS, South Korea's Bio-Health Industry Promotion Plan, Australia's RNA Sector Development Plan, and India's BioE3 Policy, all aimed at enhancing biomanufacturing capabilities and positioning Asia as a global leader in the biopharma industry.

The FDA updates mRNA COVID-19 vaccines for 2024-2025 to include KP.2 strain of Omicron JN.1 lineage, aiming for better protection. Updated vaccines available for all age groups, with specific dose recommendations based on vaccination history. Both Pfizer and Moderna confirm immediate availability.

Penn Engineers developed siloxane-incorporating lipid nanoparticles (SiLNPs) that enhance mRNA delivery to specific tissues like the liver, lungs, and spleen, potentially revolutionizing personalized medicine and gene therapy.

Study investigates pre-operative mRNA-based models for predicting biochemical recurrence (BCR) in prostate cancer, finding machine learning (ML) models, particularly random survival forest (RSF) and boosted Cox models, significantly outperform traditional nomograms. mRNA variables like DNAH8, ABCC11, ESM1, and PI15 show potential as biomarkers for early treatment decisions, paving the way for precision medicine approaches.